From the Departamento de Dermatologia, Universidade de São Paulo, Brazil.
Novant Health Dermatology Associates, Matthews, NC.
Dermatitis. 2022;33(6S):S24-S36. doi: 10.1097/DER.0000000000000864. Epub 2022 Mar 23.
Atopic dermatitis (AD) is a common, chronic, inflammatory skin condition that affects people of all ages, races, and ethnicities. The condition is heterogeneous in both clinical presentation (phenotype) and underlying pathobiology (endotype). Atopic dermatitis diagnosis, assessment, and monitoring rely on clinical evaluation because there are no definitive biomarkers for AD. This review addresses variation in the clinical presentation of AD across the spectrum of Fitzpatrick skin types, with an emphasis on clinical evaluation challenges in patients with skin of color. We present photographs from phase 3 clinical trials that evaluated the safety and efficacy of upadacitinib among patients with moderate-to-severe AD and demonstrate the challenges in evaluating the clinical signs of AD (erythema and excoriation in patients with dark skin types and lichenification in those with light skin types) by illustrating the changes in clinical signs and symptoms that can be achieved with targeted systemic therapies.
特应性皮炎(AD)是一种常见的慢性炎症性皮肤病,可发生于所有年龄段、种族和民族的人群中。该病在临床表现(表型)和潜在病理生物学(内型)方面均具有异质性。AD 的诊断、评估和监测依赖于临床评估,因为目前尚无 AD 的明确生物标志物。本综述讨论了 AD 在 Fitzpatrick 皮肤类型谱中的临床表现变化,重点介绍了在有色人种患者中进行临床评估的挑战。我们展示了评估乌帕替尼在中重度 AD 患者中的安全性和疗效的 3 期临床试验的照片,并通过说明可以通过靶向全身治疗实现的临床体征和症状的变化,说明了在深色皮肤类型患者中 AD 的临床体征(红斑和搔抓)和在浅色皮肤类型患者中苔藓样变的评估挑战。